Locally advanced non-small cell lung cancer: Do we know the questions? A survey of randomized trials from 1966-1993

Journal of Clinical Epidemiology

Volumn 49, Issue 2, 1996, Pages 183-192

  Brundage, M D ^a,b   Mackillop, W J ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Radiation Oncology Research Unit   (Canada)

Author keywords

Comparative studies; Non small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPACT DISK; DATA BASE; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; PHYSICIAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029863320     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-4356(95)00518-8     Document Type: Article

References (39)

1. DeVita VT. Lung cancer. In: VT DeVita, S Hellman, SA Rosenberg. Eds. Principles and Practice of Oncology. New York, Lippincott, 1990.
2. Boring CC, Squires TS, Tong MS, Montgomery S. Cancer statistics, 1994. Ca: Cancer J Clin 1994; 44: 7-26.
3. Anonymous. Canadian Cancer Statistics, Toronto, National Cancer Institute of Canada, 1992, pp. 18-19.
4. Novotny TE, Shane P, Daynard RA, Connolly GN. Tobacco use as a sociologic carcinogen: the case for a public health approach. Can Preven 1992; July: 1-15.
5. Green MR. Chemotherapy and radiation in the nonoperative management of stage III non-small-cell lung cancer: the right chemotherapy works in the right setting. In: VT DeVita, S Hellman, SA Rosenberg. Eds. Important Advances in Oncology 1993. Philadelphia, J.B. Lippincott, 1993, pp. 125-138.
6. Mackillop WJ, O'Sullivan B, Ward GK. Non-small cell lung cancer: how oncologists want to be treated. Int J Rad Oncol Biol Phys 1987.
7. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol 1990; 19: 17-28.
8. Mackillop WJ, Ward OK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer 1986; 54: 661-667.
9. Murray N. Chemotherapy for non-small cell lung cancer: a futile or fertile field for clinical research? Can J Clin Oncol 1993; 3: 151-160.
10. Hamilton CS, Denham JW, Joseph DJ, et al. Treatment and planning decisions in non-small cell carcinoma of the lung: an Australasian pattern of practice study. Newcastle Mater Misericordiae Hospital, New South Wales, Australia. Clin Oncol 1992; 4: 141-147.
11. Priestman TJ, Bullimore JA, Oodden TP. The Royal College of Radiologists' Fractionation Survey. Clin Oncol 1989; 1: 39-46.
12. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 1995; 13: 1904-1911.
13. Pocock SJ. Introduction: the rationale of clinical trials. In: SJ Pocock. Ed. Clinical Trials - A Practical Approach. Toronto, Wiley, 1984, pp. 1-13.
14. Hubbard SM. Information systems in oncology. In: VT DeVita, S Hellman, SA Rosenberg. Eds. Cancer: Principles and Practice of Oncology. Philadelphia, J.B. Lippincott, 1993, pp. 2581-2588.
15. Mountain CF. A new international staging system for non-small cell lung cancer. Chest 1986; 89: 225s-233s.
16. Nagy-Mignotte H, Bolla M, Wuyam B, et al. Sequential combination of 5-fluorouracil, cis-platinum and irradiation in unresectable non-small cell lung cancer. Radiother Oncol 1989; 15: 333-339.
17. Havemann K, Wolf M, Gorg C, Hackenbruch E, Pfab R, Gorg K. Preclinical and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol 1992; 3(3): 33-37.
18. Gomm SA, Thatcher N, Cuthburt A, et al. High dose combination chemotherapy with ifosfamide, cyclophosphamide orcisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. Br J Cancer 1991; 63: 293-297.
19. Mackillop WJ, Palmer MJ, O'Sullivan B, Quirt CF. The Expert Surrogate System. In: CJ Williams. Ed. Introducing New Treatments for Cancer. Toronto, Wiley and Sons, 1992, pp. 459-478.
20. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874-1881.
21. Hazuka MB, Turrisi AT. The evolving role of radiation therapy in the treatment of locally advanced lung cancer. Semin Oncol 1993; 20: 173-184.
22. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-145.
23. O'Sullivan B, Mackillop WJ. An approach to the interpretation of the literature of head and neck cancer. Clin Oncol 1986; 5: 411-433.
24. O'Sullivan B, Mackillop W, Gilbert R, et al. Controversies in the management of laryngeal cancer: results of an international survey of patterns of care. Radiother Oncol 1994; 31: 23-32.
25. Mike V. Philosophers assess randomized clinical trials: the need for dialogue. Control Clin Trials 1989; 10: 244-253.
26. Hellman S, Hellman DS. Of mice but not men: problems of the randomized clinical trial. N Engl J Med 1991; 324: 1585-1589.
27. Passamani E. Clinical trials - are they ethical? N Engl J Med 1991; 324: 1589-1591.
28. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Policies. Philadelphia, American College of Physicians, 1992, pp. 5-15.
29. Brundage MD, Davidson JR. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. Clin Invest Med 1994; Aug (suppl) (Abstract).
30. Silverman WA. The public character of scientific medicine. Perspect Biol Med 1993; 26: 343-353.
31. Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 1994; 32: 106-115.
32. Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Rad Oncol Biol Phys 1992; 24: 11-15.
33. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940-945.
34. Anonymous. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991; 63: 265-270.
35. Anonymous. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992; 65: 934-941.
36. Hilden J, Habbema JDF. The marriage of clinical trials and clinical decision science. Stat Med 1993.
37. Veatch RM, Moreno JD. Consensus in panels and committees: conceptual and ethical issues. J Med Phil 1991; 16: 371-373.
38. Wachter RM. AIDS, activism, and the politics of health. N Engl J Med 1992; 326: 128-133.
39. Gibson B. Breast cancer activists call for more research, more compassion. Can Med Assoc J 1993; 148: 254-256.